Author

C. Seiser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

W. Ellmeier· 3 shared C. Bock· 2 shared G. Egger· 2 shared M. Zrimsek· 2 shared R. Sheibani-Tezerji· 2 shared A. Hagelkrueys· 1 shared A. Malzer· 1 shared A. Meixner· 1 shared

Activity by Year

2020-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

W. Ellmeier

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy

M. Zrimsek, K. Draganic, A. Malzer, V. Doblmayr, R. de Freitas e Silva, S. Wohlhaupter, C. U. Perez Malla, K. Misura, H. Fischer, H. Schachner, A.-I. Schiefer, R. Sheibani-Tezerji, W. Ellmeier, C. Seiser, G. Egger

This study shows HDAC1 suppresses ALK-positive lymphoma growth, but systemic HDAC inhibition can still be therapeutic.

Leukemia · Apr 2, 2025Peer-reviewedCancer Biology

Targeting the catalytic activity of HDAC1 in T cells protects against experimental autoimmune encephalomyelitis

C. Zhu, V. Stolz, N. Simonovic, O. Al-Rubaye, T. Vcelkova, V. Moos, L. Hess, A. Hagelkrueys, M. Madern, W. Reiter, A. Meixner, C. Bock, M. Hartl, W. Ellmeier, C. Seiser

This study shows that inhibiting HDAC1 catalytic activity in T cells prevents experimental autoimmune encephalomyelitis by reducing proinflammatory cytokines and effector functions.

bioRxiv · Apr 14, 2023 · PreprintImmunology

Requirement of DNMT1 to orchestrate epigenomic reprogramming during NPM-ALK driven T cell lymphomagenesis

E. Redl, R. Sheibani-Tezerji, P. Hamminger, G. Timelthaler, M. R. Hassler, S. Lagger, T. Dillinger, L. Hofbauer, M. Zrimsek, A. Tiefenbacher, M. Kothmayer, C. H. Dietz, B. H. Ramsahoye, L. Kenner, C. Bock, , G. Egger

This study shows that DNMT1 is essential for maintaining tumor-specific methylation during NPM-ALK driven T cell lymphomagenesis, despite oncogenic signaling.

bioRxiv · Apr 9, 2020 · PreprintCancer Biology